BNP PARIBAS ARBITRAGE/CALL/MODERNA/140/0.01/20.12.24 | Real-time Borsa Italiana 11:02:32 28/06/2024 BST | ||
| 0.129 EUR | +7.05% |
|
| Current month | -50.82% | ||
| 1 month | -71.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 0.129 | +7.05% |
| 27/06/24 | 0.1205 | -6.59% |
| 26/06/24 | 0.129 | -36.61% |
| 25/06/24 | 0.2035 | +0.99% |
| 24/06/24 | 0.2015 | +8.92% |
Real-time Borsa Italiana
Last update June 28, 2024 at 11:02 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| P21670 | |
| ISIN | NLBNPIT21670 |
| Date issued | 26/03/2024 |
| Strike | 140 $ |
| Maturity | 20/12/2024 (176 Days) |
| Parity | 100 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.429 € |
|---|---|
| Lowest since issue | 0.0735 € |
| Spread | 0.0145 € |
| Spread % | 10.62% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.2
USD
Average target price
145.9
USD
Spread / Average Target
+20.36%
- Stock Market
- Warrants
- P21670 Warrant
